Business Wire

NC-LENOVO

Share
Lenovo Becomes the Preferred Workstation Innovation Partner for DreamWorks Animation

Lenovo™ today announced that DreamWorks Animation has selected Lenovo as its preferred workstation innovation partner to deliver the high-end power and performance needed to bring its next cutting-edge animation feature films to life. This PC collaboration further strengthens the companies’ partnership, as it expands upon the technology leader’s current role as DreamWorks’ data center innovation partner. As part of this multi-year agreement, DreamWorks will deploy Lenovo workstations, including the ThinkStation P620 and ThinkStation P920 , across all departments for the development of content and characters, including the highly anticipated release of the studio’s upcoming film, “The Bad Guys.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005429/en/

The extension of this partnership follows the rollout of a new on-premises Lenovo computing infrastructure designed to transform DreamWorks’ data center into a high-performance, ultra-scalable and sustainable operations center for all of its content creation.

With consumer demand for premium animated content at an all-time high, DreamWorks Animation looked to Lenovo’s Intelligent Devices Group to find innovative workstation solutions that could keep up with its ever-scaling ambitions, increasingly complex workflows and faster production timelines. Designed for high productivity, Lenovo workstations are engineered for power, performance and industry-leading reliability that allow artists to bring their creative ideas to life.

“At DreamWorks, the ability to operate our workflows at the speed of our creative thought process is critical in capturing those instant moments of expression that shape the unforgettable experiences our animators and creative professionals develop. Workstations need to exceed the demands of our artists’ relentless imaginations. Hardware needs to be an enabler; harnessing performance and speed to meet their expectations,” said Bill Ballew, Chief Technology Officer at DreamWorks. “We had the opportunity to test Lenovo’s ThinkStation P620 workstation and realized it’s a game changer for our workflows. Built on the AMD Ryzen™ Threadripper™ PRO architecture, the ThinkStation P620 drives new and improved performance for multi-threaded application environments that our team can take full advantage of.”

From 3D modeling, rigging, surfacing, and simulations to high performance animation and creating hyper-photorealistic renderings, DreamWorks Animation specialists, artists and engineers alike leverage high performance compute capabilities. By relying on the flexibility and future-proofed platforms that Lenovo’s workstations deliver, the DreamWorks’ team can focus on their creative ambitions knowing they are equipped with the world-class technology necessary to meet those complex workflows - now and in the years ahead. In addition to the Lenovo ThinkStation P620, DreamWorks Animation will also be able to take advantage of Lenovo’s most advanced dual processor workstation, the ThinkStation P920. Built with the latest generation of Intel® Xeon® processors, the workstation’s extreme performance will help DreamWorks accelerate their most challenging workflows in a production studio environment.

“We’re excited to expand our partnership with DreamWorks Animation and equip them with workstations that help accelerate their increasingly demanding workflows,” said Rob Herman, Vice President of Lenovo’s Workstation and Client AI Business Unit. “Our workstation collaboration further exemplifies Lenovo’s ability to holistically support our customers with the most advanced technology solutions available, allowing them to innovate faster and transform their respective industries.”

To learn more about how DreamWorks Animation is strengthening its partnership with Lenovo to bring about the next evolution of production, visit: https://techtoday.lenovo.com/us/en/workstations

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .

LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. AMD and RYZEN™ are trademarks of Advanced Micro Devices, Inc. Intel, Intel Core and vPro are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. ©2021, Lenovo Group Limited.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release

Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release

Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release

New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye